

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS
HOLDINGS INC., and APOTEX HOLDINGS, INC.,
Petitioners,

v.

OSI PHARMACEUTICALS, INC.,
Patent Owner.

U.S. Patent No. 6,900,221

Issue Date: May 31, 2005

Title of Patent: Stable Polymorph on N-(3-ethylphenyl)-6,7-bis(2methoxyethoxy)-
4-quinazolinamine hydrochloride, Methods of Production,
and Pharmaceutical uses thereof

Case No.: IPR2016-01284

PETITIONERS' UPDATED MANDTAORY NOTICES

MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))

Pursuant to 37 C.F.R. § 42.8, Petitioners Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc, respectfully submits the following updated Mandatory Notices.

I. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))

Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc. are the real parties-in-interest for Petitioners.

Apotex Inc. is an Ontario corporation organized under Canadian laws, and is wholly owned by Apotex Pharmaceuticals Holdings Inc., which itself is wholly owned by Apotex Holdings, Inc. Both Apotex Pharmaceuticals Holdings Inc. and Apotex Holdings, Inc. are Ontario corporations. Apotex Corp. is a Delaware corporation and is ultimately wholly owned by Apotex Holdings, Inc. None of Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc. are publicly traded companies.

According to U.S. Patent Office (“PTO”) records, the assignee of the ’221 patent is OSI Pharmaceuticals, Inc. (Melville, NY) (“OSI” or “Patent Owner”).

II. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))

The ’221 patent is presently at issue in the following patent infringement lawsuits:

- *OSI Pharmaceuticals, LLC and Genentech, Inc. v. Apotex Inc. and Apotex Corp.*, Civil Action No. 1:15-cv-00772-SLR (D. Del); and
- *Pfizer Inc., OSI Pharmaceuticals, LLC and Genentech, Inc. v. Breckenridge Pharmaceutical, Inc. and Natco Pharma Ltd.*, Civil Action No. 1:15-cv-01063-SLR (D. Del.).

a. Identification of Counsel (37 C.F.R. § 42.8(b)(3))

Lead Counsel	Back-Up Counsel
<p>William Blake Coblentz (Reg. No. 57,104) COZEN O'CONNOR 1200 19th Street, N.W. Washington, D.C. 20036 Telephone No.: 202-912-4837 Fax. No.: 202-861-1905 Email: wcoblentz@cozen.com</p>	<p>Aaron S. Lukas, Ph.D. (Reg. No. 59,443) COZEN O'CONNOR 1200 19th Street, N.W. Washington, D.C. 20036 Telephone No.: 202-912-4823 Fax. No.: 202-861-1905 Email: alukas@cozen.com</p> <p>Kerry B. McTigue (<i>Pro Hac Vice</i> Admission pending) COZEN O'CONNOR 1200 19th Street, N.W. Washington, D.C. 20036 Telephone No.: 202-912-4810 Fax. No.: 202-861-1905 Email: kmctigue@cozen.com</p>

b. Service Information (37 C.F.R. § 42.8(b)(4))

Please direct all correspondence to lead counsel and back-up counsel at the contact information above. Petitioners consent to service by electronic mail at the email addresses set forth above.

Dated: July 6, 2017

Respectfully Submitted,

/W. Blake Coblentz/
W. Blake Coblentz
Reg. No. 57,104
Counsel for Petitioners

COZEN O'CONNOR PC
1200 Nineteenth St. N.W.
Washington, D.C. 20036
202-912-4837
wcoblentz@cozen.com

CERTIFICATE OF SERVICE

I hereby certify that, on July 6, 2017, I caused a true and correct copy of the foregoing materials:

- PETITIONERS' UPDATED MANDATORY NOTICE

to be served via electronic mail on the following attorneys of record:

Emily Whelan
Jonathan B. Roses
Kevin M. Yurkerwich
Amy K. Wigmore
Wilmer Cutler Pickering Hale and Dorr LLP
60 State St.
Boston, MA, 02109
617-526-6000

Emily.Whelan@wilmerhale.com
Jonathan.Roses@wilmerhale.com
Kevin.Yurkerwich@wilmerhale.com
Amy.Wigmore@wilmerhale.com

By: /W. Blake Coblentz/
W. Blake Coblentz
Reg. No. 57,104
Counsel for Petitioners

COZEN O'CONNOR PC
1200 Nineteenth St. NW
Washington, D.C. 20036
202-912-4837
wcoblentz@cozen.com